- Home
- REGCP vs VRXAW Comparison
REGCP vs VRXAW Comparison
Compare REGCP & VRXAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGCP | VRXAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | REGCP | VRXAW |
|---|---|---|
| Price | $23.04 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.5K | ★ 49.5K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,553,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.08 | ★ N/A |
| Revenue Growth | ★ 6.85 | N/A |
| 52 Week Low | $22.35 | $0.08 |
| 52 Week High | $24.74 | $0.23 |
Technical Indicators
Market Signals| Indicator | REGCP | VRXAW |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 40.26 |
| Support Level | $22.98 | N/A |
| Resistance Level | $23.50 | $0.17 |
| Average True Range (ATR) | 0.14 | 0.01 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 43.16 | 8.02 |
Price Performance
Historical ComparisonAbout REGCP Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
About VRXAW Veraxa Biotech AG Warrants
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.